Lightbridge Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Lightbridge is a development-stage nuclear fuel technology company with no reported revenue; it is developing metallic fuel for water-cooled reactors. Financial statements are unaudited.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $3.18 million | $2.31 million, up 39% |
| Operating loss | $3.18 million | $2.28 million |
| Interest income | $362,000 | $256,000 |
| Net loss | $2.82 million | $2.03 million |
| Net loss per share, basic and diluted | $0.21 | $0.17 |
| Net cash used in operations | $1.88 million | $1.58 million |
| Cash and cash equivalents, March 31 | $27.94 million | $28.60 million at Dec. 31, 2023 |
| Working capital | Approximately $27.6 million | — |
Research and development expense rose to $1.02 million from $448,000, primarily reflecting greater INL activity and new Romania and Centrus studies. General and administrative expense increased 16% to $2.16 million. There are no gross margins to assess given the absence of revenue. The company reported no debt or lines of credit. Current liabilities were $907,000, versus $486,000 at year-end.
Financing provided $1.22 million of net proceeds from ATM share sales in the quarter, compared with $731,000 a year earlier. Cash declined by $656,000 overall. Common shares outstanding were 14.19 million at March 31 and 14.43 million as of May 10, 2024.
Development, outlook, and risks
- Management expects current cash resources to cover operating needs for the next 12 months, but forecasts approximately $16.2 million of expenditures over that period, including increased R&D. It projects $8–9 million of nuclear-fuel R&D investment over the next 12–15 months.
- Management estimates long-term outside R&D needs at an average of $10 million annually for 10–15 years and says continued development will require government, strategic-partner, or other third-party funding. Equity financing may dilute shareholders; access to the ATM is subject to market conditions and SEC “baby shelf” limits.
- Management’s commercialization estimates are highly uncertain: lead test rods or assemblies could be demonstrated in commercial reactors in the 2030s, with initial fuel-reload orders estimated 15–20 years from now, followed by deployment about two years later.
- INL demonstrated extrusion of a depleted-uranium/zirconium alloy rod in March. Further analysis is planned before enriched-uranium samples are produced for irradiation testing. The company added about $0.6 million to an INL task statement; outstanding INL commitments were approximately $3.1 million. Total disclosed R&D commitments were approximately $3.5 million.
- Centrus completed the initial phase of its pilot-fabrication-facility FEED study and issued a preliminary report. Lightbridge had not decided whether to proceed with the final phase, estimated to cost about $0.3 million. The Romania CANDU feasibility study is also expected to continue in 2024.
- After quarter-end, the ATM agreement was amended, including a reduction in Stifel’s commission to 3%. ATM sales from April 1 through May 10 were approximately 0.2 million shares, generating about $0.7 million net proceeds. A new $75 million shelf registration became effective April 19; the May 10 ATM supplement permits up to $6.6 million of sales, subject to applicable limits.
- Disclosure controls were deemed ineffective as of March 31 because of an unremediated material weakness in IT access controls and segregation of duties. Management reported no related financial-statement restatement or changes to previously reported results; remediation and testing remain ongoing.
- Key risks include technical and regulatory uncertainty in fuel development, dependence on government laboratories and partners, future financing needs, possible dilution, competitive technologies, testing availability, and uncertain development costs and timelines. The filing reports no legal proceedings believed to be materially adverse.
Most important facts for investors to verify
- Whether INL testing milestones, including enriched-fuel irradiation testing, remain on schedule and within the disclosed commitments.
- Actual cash burn and R&D spending versus management’s $16.2 million 12-month expenditure estimate and $8–9 million R&D projection.
- Available ATM capacity under the baby shelf rules, subsequent share issuance, and resulting dilution.
- Whether strategic, government, or other funding is secured for the long development period beyond management’s 12-month liquidity outlook.
- Progress in remediating and testing the disclosed material weakness in internal controls.